Neurocrine Biosciences develops and commercializes medicines for neurological and endocrine diseases. Its work centers on discovering and developing treatments, with INGREZZA (valbenazine) approved to treat adults with tardive dyskinesia and a pipeline of other drug candidates in various clinical stages. The company earns revenue from sales of approved medicines and from milestones and royalties from collaborations with partners. By focusing on both neurological and endocrine conditions, Neurocrine targets patients and healthcare professionals seeking therapies for conditions such as tardive dyskinesia, Parkinson's disease, and endometriosis. Its main goal is to bring therapies to market through development and commercialization, supported by ongoing research across its clinical programs to address unmet medical needs in these areas.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
1992
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?